“We are, for instance, supporting a grant, which develops a cooling soul, for sneakers for patients. Patients, some patients, and too many patients have problems with defeat with blisters on defeat and problems with wearing sneakers. So, we're we're supporting a group that develops a self cooling soul, which can be put into into, sneakers.”
→ Read the source episode
A self-cooling sole product for sneakers is developed and becomes available for EB patients.
Jean Mack predicts Phase 2 will enroll patients across Australia, potentially Europe, and the United States
Deborah Research will identify and move the most promising read-through molecule candidates into first-in-human clinical studies.
Jean Mack predicts GAIN's IND will be cleared by the FDA within weeks and Phase 2 will begin in Q3 2026
Lu Gao predicts Therona will file INDs in parallel in the US and China in Q4 2026
Andy Parker predicts StepPharma will raise additional funding within next six months (by January 2027).
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.